Revolution Medicines Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $251.21. The average 1-year stock price forecast is 30.09% higher than the current stock price, while the lowest is $179 (-7.31%) and the highest is $320 (+65.71%).

Price Target: $251.21 (+30.09%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$179	$251.21	$249.5	$320
Change	-7.31%	+30.09%	+29.20%	+65.71%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	17	17	17	17	17	16
Buy	4	4	4	4	4	4
Hold	0	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	21	22	22	22	22	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $225 → $265	Buy	Maintains	$225 → $265	+37.23%	Sep 21, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $251	Buy	Maintains	$251	+29.98%	Sep 16, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $315	Buy	Maintains	$315	+63.12%	Sep 14, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $215 → $230	Buy	Maintains	$215 → $230	+19.10%	Sep 13, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Initiates $255	Buy	Initiates	$255	+32.05%	Sep 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

169.72M

Revenue Next Year

1.24B

from 169.72M

633.50%

from 169.72M

EPS This Year

-9.73

from -5.95

EPS Next Year

-5.95

from -9.73

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	169.72M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	149.24M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	87.93%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.94B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-2.04B
EPS	-	-	-	-	-5.95	-9.73
Free Cash Flow	-	-	-	-	-913.73M	-1.68B
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	338.6M
Avg	169.7M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	1,314.1%
Avg	633.5%
Low	262.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-8.35
Avg	-9.73
Low	-12.35

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-